Septerna

This National Disability Employment Awareness Month, we celebrate the invaluable contributions and unique perspectives of people with disabilities in our workforce and beyond.    At Septerna, we recognize that the creativity, resilience, and problem-solving skills that individuals with disabilities bring to the workplace strengthen our mission and enrich our team every day.    We’re proud of our inclusive culture where everyone has the support they need to thrive and do their best work together.    #NDEAM #DisabilityEmploymentAwarenessMonth #Inclusion #Accessibility #TeamSepterna #Diversity #Innovation #Biotechnology 

This Hispanic Heritage Month, we celebrate the rich contributions and profound impact of Hispanic and Latino Americans throughout history and within our own #TeamSepterna.  At Septerna, we recognize that innovation thrives when we embrace the full spectrum of experiences, backgrounds, and viewpoints that make our team extraordinary.  Today and every day, we’re committed to fostering an inclusive environment where every voice is heard, every contribution is valued, and every team member can bring their authentic self to the important work we do together. #HispanicHeritageMonth #HHM2025 #LatinoHeritage #Diversity #Inclusion #TeamSepterna

We’re proud to sponsor the International HypoPARAthyroidism Conference, bringing together patients, caregivers, researchers, and healthcare professionals united in advancing care for the hypoparathyroidism community. Thank you to HypoPARAthyroidism Association and all conference organizers for creating this vital platform for collaboration, education, and hope. Together, we’re working toward a future where no one faces this journey alone and new treatments improve patients’ lives. Learn more: https://lnkd.in/grsXcjVs #InternationalHypoparaConference #hypoparathyroidism #hypopara #PatientsInspireOurUrgency #Endocrinology 

We recently came together to celebrate the incredible talent that makes up #TeamSepterna!      Our team brings together exceptional expertise, and we’re grateful for each colleague’s unique skills and passion that enable our tenacious pursuit of discovering and developing impactful medicines for patients. We strongly believe in collaboration and innovation, and it’s our shared purpose that motivates us every day.     At Septerna, we pride ourselves on our unique culture. It is our secret sauce that attracts exceptional talent, keeps our team engaged, and creates the magic that makes Septerna as special as our unicorn mascot! Here’s to continued momentum and the potential therapies we’ll discover and develop together! #TeamWork #GPCRs #Innovation #Biotechnology #PatientsInspireOurUrgency #Culture #TeamCelebration #UniqueTeam  

We’re excited to welcome Keith Gottesdiener, M.D., a veteran biotechnology leader with over 30 years of experience, to Septerna’s Board of Directors!    Dr. Gottesdiener will serve as chairperson of our newly constituted R&D Committee, bringing exceptional expertise from his leadership roles at Prime Medicine, Rhythm Pharmaceuticals, and Merck Research Laboratories, where he oversaw the approval of more than 20 novel therapeutics.    His proven track record of advancing novel therapeutics from discovery through development to approval will be invaluable as we advance our clinical programs and continue building our pipeline of potential differentiated GPCR therapies using our proprietary Native Complex Platform™.    Read the full announcement: https://lnkd.in/gDVixG5z   #BoardOfDirectors #BiotechLeadership #GPCR #DrugDiscovery #TeamSepterna #LifeSciences #Biotech #Leadership #ClinicalDevelopment 

We are looking forward to participating in two upcoming investor conferences this September.    Join our leadership team at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 3rd at 11:30 AM EST in New York.     We'll also be at the Wells Fargo Healthcare Conference on Thursday, September 5th at 8:45 am EST in Boston.    Can’t make it in person? A live webcast will be available and archived for 30 days following each presentation. Full details here: https://lnkd.in/ggrt7xvA #BiotechInnovation #GPCRs #CantorHealthcare #WellsFargoHealthcare  

We’re thrilled to share that the first participants were dosed in our Phase 1 trial of SEP-631, a selective oral small molecule Mas-related G-protein coupled receptor X2 (MRGPRX2) negative allosteric modulator being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.    This trial represents a significant step forward for the millions affected by mast cell-driven diseases.    Read the full announcement: https://lnkd.in/gSsaQWmt   #MRGPRX2 #ChronicUrticaria #MastCells #GPCR #ClinicalTrials #DrugDiscovery #PhaseOne #ClinicalResearch 

What an incredible day at our #TeamSepterna Summer Picnic!  From giant Jenga and cornhole competitions to face painting and arts & crafts for the kids, our team came together to celebrate the community that powers our mission.     Watching our colleagues’ families enjoy lawn games and great food reminded us why “Collaboration powers our community” extends far beyond the workplace.    When we invest in our people and their families, we invest in the innovation that will bring life-changing therapies to patients.    Here's to the incredible team that makes Septerna not just a place to work, but a community to belong to!    #LifeAtSepterna #TeamBuilding #SummerPicnic #CompanyCulture #Community #WorkFamily #Biotechnology #GPCRDrugDiscovery 

July is Graves’ Disease Awareness Month This month, we stand with the over 2 million Americans living with Graves’ disease, the leading cause of hyperthyroidism. For many patients, this autoimmune condition brings challenging symptoms like anxiety, tremors, and fatigue. Nearly half will also develop thyroid eye disease (TED), a serious condition that can threaten vision and significantly impact quality of life. At Septerna, we’re committed to advancing new treatment options. Our TSHR program is developing an oral small molecule approach that could directly target the underlying cause of both Graves’ disease and TED by blocking the overactivation of thyroid stimulating hormone receptors. We believe in the power of innovative science to transform lives. Learn more about our TSHR program: https://lnkd.in/eE4nMurn #GravesDiseaseAwarenessMonth #GDAM #ThyroidHealth 

We’re thrilled to welcome two exceptional leaders to #TeamSepterna! Please join us in welcoming David Lau as Vice President, DMPK/Clinical Pharmacology and Elizabeth Alexander as Vice President, Clinical Development. David will lead our clinical pharmacological strategy from preclinical through clinical development, while Elizabeth will spearhead our clinical development strategy and lead programs from early to late-stage clinical development. Both David and Elizabeth bring expertise and extensive experience to Septerna’s growing development organization, and they will play instrumental roles in delivering impactful new GPCR-targeted therapies to patients with high unmet medical needs.   #Biotech #DrugDiscovery #GPCR #NewHire #WelcomeToTheTeam #Leadership #LifeSciences #BiotechJobs #ClinicalDevelopment